


Data supplement for Rodriguez et al., Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept. Am J Psychiatry (doi: 10.1176/appi.ajp.2016.16080868).

Figure S1. Box Plots of the Obsessive-Compulsive, Depression, and Anxiety Severity Scores at Baseline, 90 Minutes, and 230 Minutes After a Single Infusion of Rapastinel (N=7)^a



^a At baseline, 90, and 230 minutes postinfusion (rapastinel 10mg/kg), patients self-rated the severity of their: a) obsessions and compulsions (YBOCCS [range 0–40]), b) anxiety (BAI [range 0–63]), and c) depression (BDI [range 0–63]). For the 90 and 230 minute assessments, patients were instructed to rate their symptoms over the past 60 minutes for all three measures. Box plots illustrate the first quartile (bottom of box), third quartile (top of box), median (dark line), mean score (red circle), and maximum and minimum (lines extending vertically from the boxes), except for outliers (black circle). YBOCCS=Yale-Brown Obsessive Compulsive Challenge Scale; BAI=Beck Anxiety Inventory; BDI=Beck Depression Inventory.